Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Abeona Therapeutics Inc. (ABEO : NSDQ)

• Company Description    Abeona Therapeutics, Inc. is engaged in developing and delivering gene therapy and plasma-based products for rare diseases. Abeona Therapeutics Inc., formerly known as PlasmaTech Biopharmaceuticals, Inc., is based in Dallas, United States. Number of Employees: 226

• Price / Volume Information    Yesterday's Closing Price: $4.40 Daily Weekly Monthly 20 Day Moving Average: 1,179,914 shares Shares Outstanding: 57.18 (millions) Market Capitalization: $251.61 (millions) Beta: 1.31 52 Week High: $7.65 52 Week Low: $4.00 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -18.97% -18.11% 12 Week -31.99% -33.65% Year To Date -16.51% -24.23%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 6555 Carnegie Avenue 4thFloor - Cleveland,OH 44103 USA ph: 646-813-4701 fax: 214-905-5101 ir@abeonatherapeutics.com http://www.abeonatherapeutics.com

• General Corporate Information    Officers Vishwas Seshadri - President; Chief Executive Officer Michael Amoroso - Chairman of the Board Joseph Vazzano - Chief Financial Officer Leila Alland - Director Mark J. Alvino - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 00289Y206 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 06/01/26 Next Expected EPS Date: 11/11/26 Share - Related Items Shares Outstanding: 57.18 Most Recent Split Date: 7.00 (0.04:1) Beta: 1.31 Market Capitalization: $251.61 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.09 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.88 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 6.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 11/11/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 1.96 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 39.66% vs. Previous Quarter: -16.67% Sales Growth vs. Year Ago Period: 2,745.00% vs. Previous Quarter: 30.50% ROE 09/30/26 - - 06/30/26 - -41.69 03/31/26 - -53.98 ROA 09/30/26 - - 06/30/26 - -30.36 03/31/26 - -38.52 Current Ratio 09/30/26 - - 06/30/26 - 6.63 03/31/26 - 5.89 Quick Ratio 09/30/26 - - 06/30/26 - 6.40 03/31/26 - 5.70 Operating Margin 09/30/26 - - 06/30/26 - - 03/31/26 - - Net Margin 09/30/26 - - 06/30/26 - - 03/31/26 - - Pre-Tax Margin 09/30/26 - - 06/30/26 - -306.81 03/31/26 - 455.56 Book Value 09/30/26 - - 06/30/26 - 2.25 03/31/26 - 2.55 Inventory Turnover 09/30/26 - - 06/30/26 - 1.51 03/31/26 - 0.89 Debt-to-Equity 09/30/26 - - 06/30/26 - 0.01 03/31/26 - 0.03 Debt-to-Capital 09/30/26 - - 06/30/26 - 1.28 03/31/26 - 3.18

Powered by Zacks Investment Research ©